CBDL Stock Overview
Engages in the development and marketing a line of cannabidiol based organic products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CBD Life Sciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.00055 |
| 52 Week High | US$0.03 |
| 52 Week Low | US$0.0003 |
| Beta | 54.55 |
| 11 Month Change | -60.71% |
| 3 Month Change | -31.25% |
| 1 Year Change | 83.33% |
| 33 Year Change | -99.39% |
| 5 Year Change | -99.93% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| CBDL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 83.3% | 1.6% | 2.2% |
| 1Y | 83.3% | 9.9% | 31.6% |
Return vs Industry: CBDL exceeded the US Pharmaceuticals industry which returned 10% over the past year.
Return vs Market: CBDL exceeded the US Market which returned 31.7% over the past year.
Price Volatility
| CBDL volatility | |
|---|---|
| CBDL Average Weekly Movement | 52.8% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CBDL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CBDL's weekly volatility has decreased from 5502% to 53% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 4 | Lisa Nelson | lbcbioscienceinc.com |
CBD Life Sciences Inc. engages in the development and marketing a line of cannabidiol based organic products. Its cannabidiol based organic products include hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions supplements, edibles, coffee, wine, skincare line, tablets, and a line of pet products. The company is based in Scottsdale, Arizona.
CBD Life Sciences Inc. Fundamentals Summary
| CBDL fundamental statistics | |
|---|---|
| Market cap | US$1.53m |
| Earnings (TTM) | -US$107.44k |
| Revenue (TTM) | US$178.45k |
8.6x
P/S Ratio-14.2x
P/E RatioIs CBDL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CBDL income statement (TTM) | |
|---|---|
| Revenue | US$178.45k |
| Cost of Revenue | US$98.04k |
| Gross Profit | US$80.41k |
| Other Expenses | US$187.84k |
| Earnings | -US$107.44k |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.000039 |
| Gross Margin | 45.06% |
| Net Profit Margin | -60.21% |
| Debt/Equity Ratio | 0% |
How did CBDL perform over the long term?
See historical performance and comparison